Abstract:K-Cl co-transporter 2 (KCC2/SLC12A5) is a neuronal specific cation chloride co-transporter which is active under isotonic conditions, and thus a key regulator of intracellular Cl levels. It also has an ion transporter-independent structural role in modulating the maturation and regulation of excitatory glutamatergic synapses. KCC2 levels are developmentally regulated, and a postnatal upregulation of KCC2 generates a low intracellular chloride concentration that allows the neurotransmitters γ-aminobutyric acid … Show more
“…The activity of KCC2 is regulated not only by expression level but also through various other mechanisms, such as phosphorylation/de-phosphorylation [130][131][132] and membrane trafficking [133][134][135]. For example, phosphorylation of threonine residues 906 and 1007 decreases the activity of KCC2.…”
Section: Developmental Changes In Gabaergic and Glycinergic Actionmentioning
confidence: 99%
“…The phosphorylation of tyrosine residue 1087 is involved in internalization of KCC2, which results in the down-regulation of KCC2 activity [135]. In addition to tyrosine residue phosphorylation, other complex mechanisms may play roles in trafficking and endocytosis of KCC2 and regulate the activity of KCC2 in developing neurons [133][134][135].…”
Section: Developmental Changes In Gabaergic and Glycinergic Actionmentioning
Gamma-aminobutyric acid (GABA) and glycine act as inhibitory neurotransmitters. Three types of inhibitory neurons and terminals, GABAergic, GABA/glycine co-releasing, and glycinergic, are orchestrated in the spinal cord neural circuits and play key roles in the regulation of pain, locomotive movement, and respiratory rhythms. Herein, we first describe GABAergic and glycinergic transmission and inhibitory networks, which consist of three types of terminals, in the mature mouse spinal cord. Second, we describe the developmental formation of GABAergic and glycinergic networks, with specific focus on the differentiation of neurons, formation of synapses, maturation of removal systems, and changes in their action. GABAergic and glycinergic neurons are derived from the same domains of the ventricular zone. Initially, GABAergic neurons are differentiated and their axons form synapses. Some of these neurons remain GABAergic in lamina I and II. Many of GABAergic neurons convert to co-releasing state. The co-releasing neurons and terminals remain in the dorsal horn, whereas many of co-releasing ones ultimately become glycinergic in the ventral horn. During the development of terminals and the transformation from radial glia to astrocytes, GABA and glycine receptor subunit compositions markedly change, removal systems mature, and GABAergic and glycinergic action shifts from excitatory to inhibitory.
“…The activity of KCC2 is regulated not only by expression level but also through various other mechanisms, such as phosphorylation/de-phosphorylation [130][131][132] and membrane trafficking [133][134][135]. For example, phosphorylation of threonine residues 906 and 1007 decreases the activity of KCC2.…”
Section: Developmental Changes In Gabaergic and Glycinergic Actionmentioning
confidence: 99%
“…The phosphorylation of tyrosine residue 1087 is involved in internalization of KCC2, which results in the down-regulation of KCC2 activity [135]. In addition to tyrosine residue phosphorylation, other complex mechanisms may play roles in trafficking and endocytosis of KCC2 and regulate the activity of KCC2 in developing neurons [133][134][135].…”
Section: Developmental Changes In Gabaergic and Glycinergic Actionmentioning
Gamma-aminobutyric acid (GABA) and glycine act as inhibitory neurotransmitters. Three types of inhibitory neurons and terminals, GABAergic, GABA/glycine co-releasing, and glycinergic, are orchestrated in the spinal cord neural circuits and play key roles in the regulation of pain, locomotive movement, and respiratory rhythms. Herein, we first describe GABAergic and glycinergic transmission and inhibitory networks, which consist of three types of terminals, in the mature mouse spinal cord. Second, we describe the developmental formation of GABAergic and glycinergic networks, with specific focus on the differentiation of neurons, formation of synapses, maturation of removal systems, and changes in their action. GABAergic and glycinergic neurons are derived from the same domains of the ventricular zone. Initially, GABAergic neurons are differentiated and their axons form synapses. Some of these neurons remain GABAergic in lamina I and II. Many of GABAergic neurons convert to co-releasing state. The co-releasing neurons and terminals remain in the dorsal horn, whereas many of co-releasing ones ultimately become glycinergic in the ventral horn. During the development of terminals and the transformation from radial glia to astrocytes, GABA and glycine receptor subunit compositions markedly change, removal systems mature, and GABAergic and glycinergic action shifts from excitatory to inhibitory.
“…The authors showed with co-transfection experiments that full-length APP, but not its proteolytic fragments, stabilized KCC2 levels. Functional expression of KCC2 at the neuronal cell surface is necessary for its Cl − efflux activity, and the trafficking of KCC2 to the cell surface and its subsequent endocytic internalization is regulated by different cellular mechanisms, with defects in these known to underlie a range of neuropathological conditions [58]. One such regulatory mechanism is the tyrosine phosphorylation of KCC2 mediated by tyrosine kinases, such as Src [81,82,83], which promotes KCC2 internalization from the plasma membrane and its subsequent lysosomal degradation.…”
Section: App’s Modulation Of Gabaergic Neurotransmission Through Pmentioning
confidence: 99%
“…GABA A R functions as ligand-gated chloride (Cl − ) channels and whether GABA binding would be depolarizing or hyperpolarizing is largely determined by intracellular Cl − concentrations and the GABA reversal potential (E GABA ). Resting Cl − concentration in central nervous system (CNS) neurons is determined by the activity of two major cation-chloride cotransporters, namely the Cl − influx-mediating Na + -K + -2Cl − cotransporter 1 (NKCC1) and the efflux-mediating K + -Cl − cotransporter 2 (KCC2) [58]. In the adult brain, GABA is mainly hyperpolarizing and inhibitory, but it is primarily depolarizing and excitatory in developing neurons, as demonstrated using rat embryonic and neonatal cortical slices [59].…”
The amyloid precursor protein (APP) is the parent polypeptide from which amyloid-beta (Aβ) peptides, key etiological agents of Alzheimer’s disease (AD), are generated by sequential proteolytic processing involving β- and γ-secretases. APP mutations underlie familial, early-onset AD, and the involvement of APP in AD pathology has been extensively studied. However, APP has important physiological roles in the mammalian brain, particularly its modulation of synaptic functions and neuronal survival. Recent works have now shown that APP could directly modulate γ-aminobutyric acid (GABA) neurotransmission in two broad ways. Firstly, APP is shown to interact with and modulate the levels and activity of the neuron-specific Potassium-Chloride (K+-Cl−) cotransporter KCC2/SLC12A5. The latter is key to the maintenance of neuronal chloride (Cl−) levels and the GABA reversal potential (EGABA), and is therefore important for postsynaptic GABAergic inhibition through the ionotropic GABAA receptors. Secondly, APP binds to the sushi domain of metabotropic GABAB receptor 1a (GABABR1a). In this regard, APP complexes and is co-transported with GABAB receptor dimers bearing GABABR1a to the axonal presynaptic plasma membrane. On the other hand, secreted (s)APP generated by secretase cleavages could act as a GABABR1a-binding ligand that modulates presynaptic vesicle release. The discovery of these novel roles and activities of APP in GABAergic neurotransmission underlies the physiological importance of APP in postnatal brain function.
“…KCC2 transcript levels could be downregulated by neuronal activity [11,12] and brain-derived growth factor (BDNF)-TrkB signaling [13], and its post-translational functional activity is mainly determined by the level of expression at the plasma membrane. The 12-transmembrane KCC2 protein oligomerises, and its membrane trafficking [14], as well as "diffusion-trapping" [15] at the plasma membrane is modulated by neuronal activity-dependent phosphorylation/dephosphorylation of key serine and threonine residues at its cytoplasmic loops. Phosphorylation of S940 of KCC2 by protein kinase C (PKC) [16], for example, is known to stabilize KCC2 at the cell surface and reduces its internalization, whereas excitatory input through the NMDA receptor dephosphorylate S940 by protein phosphatase 1 (PP1) [12] downregulates KCC2's Cl − efflux activity.…”
Dysfunctions in GABAergic inhibitory neural transmission occur in neuronal injuries and neurological disorders. The potassium–chloride cotransporter 2 (KCC2, SLC12A5) is a key modulator of inhibitory GABAergic inputs in healthy adult neurons, as its chloride (Cl−) extruding activity underlies the hyperpolarizing reversal potential for GABAA receptor Cl− currents (EGABA). Manipulation of KCC2 levels or activity improve symptoms associated with epilepsy and neuropathy. Recent works have now indicated that pharmacological enhancement of KCC2 function could reactivate dormant relay circuits in an injured mouse’s spinal cord, leading to functional recovery and the attenuation of neuronal abnormality and disease phenotype associated with a mouse model of Rett syndrome (RTT). KCC2 interacts with Huntingtin and is downregulated in Huntington’s disease (HD), which contributed to GABAergic excitation and memory deficits in the R6/2 mouse HD model. Here, these recent advances are highlighted, which attest to KCC2’s growing potential as a therapeutic target for neuropathological conditions resulting from dysfunctional inhibitory input.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.